Pfizer: sells candidate drug to Biogen

(CercleFinance.com) - Biogen has announced an agreement to buy Pfizer's PF-04958242, a candidate drug for cognitive impairment associated with schizophrenia, for which the group plans to initiate a Phase 2b trial in the second half of 2018.


The purchase includes an upfront payment of 75 million dollars, development and commercial milestone payments of up to 515 million dollars, and tiered royalties representing percentages of around 10% to 15%.

There are over 20 million people in the world living with schizophrenia and it is estimated that the majority of them live with some cognitive impairment attributable to this disease, the laboratory specialising in neuroscience explained.


Copyright (c) 2018 CercleFinance.com. All rights reserved.